首页
登录
职称英语
Jonas Frisen had his eureka moment in 1997. Back then, scientists suspected t
Jonas Frisen had his eureka moment in 1997. Back then, scientists suspected t
游客
2023-12-17
5
管理
问题
Jonas Frisen had his eureka moment in 1997. Back then, scientists suspected that there was a special type of cell in the brain that had the power to give rise to new brain cells. If they could harness these so-called neural stem cells to regenerate damaged brain tissue, they might someday find a cure for such brain diseases as Alzheimer’s and Parkinson’s. But first they had to figure out where neural stem cells were and what they looked like. Frisen, then a freshly minted Ph. D. at the Karolinska Institute in Stockholm, was peering through his microscope at some tissue taken from a rat’s injured spinal cord when he saw cells that appeared to have been enervated by the injury, as though they were busy making repairs. Frisen thought these might be the neural stem cells scientists had been looking for. It took him six years of painstaking research to make sure.
Frisen is quick to emphasize that his research is basic and that treatments are years off. But the findings so far hint at extraordinary potential. Two years ago he identified neural stem cells in the adult humanbrain. And he’s now researching the mechanisms by which these ceils grow into different types of brain cells. Rather than growing brain tissue in a petri dish and implanting it in, say, the forebrain of a Parkinson’s patient, doctors might someday stimulate the spontaneous growth of new neural ceils merely by administering a drug. "It sounds like science fiction," Frisen says, "but we can already do it in mice." In 2007 he will publish the results of his recent experiments, lie’s isolated a protein in the mouse brain that inhibits the generation of nerve cells. Using other chemicals, he’s been able to block the action of this inhibitor, which in turn leads to the production of new brain cells.
Frisen honed his analytical mind at the dinner table in Goteborg, in southwest Sweden. His mother was a mathematics professor and his father was an ophthalmologist. Frisen went to medical school intending to be a brain surgeon or perhaps a psychiatrist, but ended up spending all his free time in the lab. In 1998 he got seed money from a Swedish venture capitalist to set up his own company, NeuroNova, to commercialize his work. A private foundation tried to lure him to Texas, but Swedish businessman Marcus Storch persuaded him to stay by funding a IS-year professorship at Karolinska, covering his salary and the running costs of his 15-person lab. "Jonas Frisen stood out from all candidates by far," says Storch, who*Ic Tobias Foundation sponsors stem-cell research. "He is something of a king in Sweden." Two years ago two more venture capitalists helped the company expand by hiring a CEO and setting up a separate lab.
Since most researchers are interested in stem cells taken from embryos, the practice has attracted considerable controversy in the past few years. Frisen has benefited indirectly from research restrictions in the United States, which have driven funds and brain-power to Singapore, the United Kingdom and Sweden. The Bush Administration currently forbids U. S. -funded work on all but 78 approved stem-cell cultures, many of which are located outside the country. In just one sign of the times, the U. S. -based Juvenile Diabetes Research Foundation recently announced grants totaling $ 20 million for stem cell research--the largest award yet given to the field by a medical charity--to research institutes in Sweden and elsewhere, but not in the United States.
Since Frisen doesn’t work with embryonic stem cells, he’s unwittingly become a champion of the radical right, which argues that scientists ought to concentrate solely on adult stem cells. He happens to disagree. "It would be overoptimistic or outright stupid." he says. "To really understand adult cells, we need to master how embryonic stem cells work." But what really gets Frisen going is when people ask him when they can expect a drug for Parkinson’s and other diseases. "I say, five decades, just to get the number thing out of the way," he quips. "I’m not going to oversell this." When pressed, he admits that clinical trials might begin in five years. That would be a eureka moment worth waiting for. [br] As to the stem-cell research, the Bush Administration’s attitude is one of ______.
选项
A、skepticism.
B、disapproval.
C、ambivalence.
D、prudence.
答案
B
解析
态度题。由题干中的the Bush Administration定位至第四段。第三句指出布什政府现在禁止干细胞培养项目,即使同意的一些项目也是在国外进行的。可见,布什政府对体细胞研究持否定态度,故[B]为答案。[C]意为“举棋不定”,与文意不符,排除。[D]意为“审慎的”,程度不够,排除。
转载请注明原文地址:https://www.tihaiku.com/zcyy/3282525.html
相关试题推荐
TheFederationofAmericanScientistsbelievesthat[br]What’sHowell’sreactio
TheFederationofAmericanScientistsbelievesthat[br]Somepeopleareopposed
JonasFrisenhadhiseurekamomentin1997.Backthen,scientistssuspected
Foronebriefmoment,afteryearsoffearandloathing,Americaseemedready
Howdothescientistsmeasurethepitch?[br][originaltext]VoiceOne:This
【B1】[br]【B3】destructive→nondestructive本题考查逻辑关系。由上文的“scientistshavetostudy
Ordinarypeople’slivesaregovernedbyformsandnoticefromthemoment
Ordinarypeople’slivesaregovernedbyformsandnoticefromthemoment
Ordinarypeople’slivesaregovernedbyformsandnoticefromthemoment
Ordinarypeople’slivesaregovernedbyformsandnoticefromthemoment
随机试题
[originaltext]Georgehadstolensomemoney,butthepolicehadcaughthimandh
Thefollowingpassageisanotice.Afterreadingit,youshouldgivebriefa
WH0于1981年提出了到2000年全球应达到的全球性卫生发展具体目标,不包括(
下列速度标记由慢到快排序正确的是()A.Largo—Andante—Alle
A.异染颗粒染色B.芽胞染色C.抗酸染色D.墨汁负染色E.镀银染色新型隐球菌用
一张工作票中,()不得互相兼任。A.工作许可人与工作负责人 B.工作票
某办公大楼,建筑高度51m,每层建筑面积3000㎡,耐火等级一级,按照国家现行技
简述现代企业人力资源管理各个历史发展阶段的特点。
下列选项中,不属于法人信贷业务操作风险成因的是()。A.片面追求贷款规模和市场份
商业银行当前的外汇敞口头寸如下:法郎空头20,日元多头50,马克多头100,英镑
最新回复
(
0
)